Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells. POLLUX was an open-label, randomised phase 3 study conducted in 18 countries that evaluated the combination of daratumumab and lenalidomide and dexamethasone (daratumumab group) compared with lenalidomide and dexamethasone (control group) in 569 patients with relapsed or refractory multiple myeloma who received at least 1 prior line of therapy. At the pre-planned interim analysis, an unprecedented 63% reduction in the risk of progression or death was shown in the daratumumab group compared with control group, leading to early unblinding of the study. More patients achieved an overall response in the daratumumab group compared with the control group (93% vs 76%, P <0.0001). Deep and durable responses were significantly more frequent in the daratumumab group, with higher rates of very good partial response or better (76% vs 44%, P <0.0001) and a more than doubling of complete response or better (43% vs 19%, P <0.0001). Treatment was well-tolerated in the daratumumab group with adverse events consistent with the known profiles of the drugs in the combination. The study establishes a positive benefit/risk profile for daratumumab with lenalidomide and dexamethasone in multiple myeloma patients who have received at least 1 prior line of therapy and suggests that this combination may represent a new standard of care for these patients.

Presenter: Dr Meletios A Dimopoulos

Affiliation: National and Kapodistrian University of Athens, Greece

Topic: AN OPEN-LABEL, RANDOMISED PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX

Abstract LB2238 will be presented by Meletios A Dimopoulos on Friday, June 10, 2016, 16:50 - 17:00 in Hall A1.

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.

Contact

EHA Executive Office

Ineke van der Beek, Jon Tarifa

E-mail: communication@ehaweb.org

Mobile: +31(0)6 2011 1055

 

Last Updated on Tuesday 05 June 2018.